DM4 （ravtansine） is a thiol-containing derivative of maytansine.
It binds to tubulin and inhibits the assembly of microtubules.
DM4 is being investigated as the cytotoxic payload of a number of antibody-drug conjugates （ADCs）.
This BSA-DM4 conjugate is designed with similar linker chemistry as commercial drug T-DM1 and is synthesized at CellMosaic® for our customers' usage in immunization or immunoassay.
Maleimide functional groups are first introduced to the BSA followed by reaction of the maleimide group with the thiol of DM4 to form the conjugate.The final conjugate is lyophilized from phosphate buffered saline containing sugar-based stabilizer for easy shipping and storage.
The product is sold as either 1 vial of 1 mg （Cat# CM52112-1MG） or 5 vials of 1 mg （Cat# CM52112-5MG）.
